23andMe's interim CEO stated that 15% of its customers, around 1.9 million people, requested deletion of their genetic data following the company's bankruptcy protection filing in March.
During a House Oversight Committee hearing, concerns were raised about the sale of 23andMe after bankruptcy, with fears of customers' data falling into wrong hands.
Regeneron, a pharmaceutical giant, won the bankruptcy auction for 23andMe with a bid of $256 million, pledging to maintain privacy practices and utilize the genetic data for drug discovery.
A federal court is set to review Regeneron's bid for 23andMe in June.
23andMe's bankruptcy follows a data breach affecting 6.9 million customers due to lack of multi-factor authentication, with blame initially placed on customers.
Several states, including Florida, New York, and Pennsylvania, have sued 23andMe over concerns about the sale of customers' private data without explicit consent.
Customers seeking to delete their 23andMe data can refer to a guide available on TechCrunch.